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We report on a 12-month-old girl with an ectopic atrial tachycardia successfully treated
with the combination of a beta blocking agent and Ivabradine that acts on cardiac
pacemaker cells by selectively inhibiting the If channel. Standard therapy had failed to
control the tachycardia before. No side effects attributable to Ivabradine were noticed.
Due to its mechanism of action Ivabradine is a promising novel agent for the therapy of
tachycardia due to increased automaticity. Reports on the use of Ivabradine in young
children or infants are rare, but show promising results for congenital junctional ectopic
tachycardia. This report adds the second case of ectopic atrial tachycardia in this age
group and novel treatment with Ivabradine to the literature.
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BACKGROUND
Ectopic atrial tachycardia (EAT) is a known cause of supraventricular tachycardia in children (1).
Due to its incessant nature it can lead to a tachycardia induced cardiomyopathy. In younger
children it is mostly responsive to antiarrhythmic medication, but a considerable number of
patients is not sufficiently treated by a first line regime and needs a combination of two or
more antiarrhythmic drugs. As spontaneous resolve is common in this age group, therapy
usually should be continued for an average time of 1 year. In older children (≥3 years) failure
of antiarrhythmic medication regimes is more common and early radiofrequency ablation is a
reasonable approach (2).
Ivabradine lowers the heart rate by selectively inhibiting a mixed sodium-potassium inward
current (If) controlling the spontaneous diastolic depolarization in pacemaker cells (3) and was
FDA-approved for stable chronic heart failure in adults. With respect to its mechanism of action
it is a promising agent for therapy of tachycardia due to increased automaticity. In the pediatric
age group there are currently only case reports and a few small case series published. While two
case series demonstrated a promising effect with congenital junctional ectopic tachycardia (JET)
in infants (4, 5), reports on its application in EAT are limited to older children and adults (6–9).
Reports on the use of Ivabradine in infants or/and young children with EAT are scarce (9).
Here, we report the successful use of Ivabradine in combination with a beta blocker for the
therapy of EAT in an 1-year old girl.
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An one-year old girl presented a persistent tachycardia during
a routine visit at the local pediatrician and was immediately
transferred to KUNO university hospital. There had been a
benign febrile infection 1 week prior to admission. Personal
and family history was non-contributory to the tachycardia. Six
months before, the previous check at the pediatrician had been
uneventful. On admission she had mild signs of heart failure
with delayed capillary refill time (3 s) and an enlarged liver. She
had a tachycardia with 240 beats/min. Echocardiography showed
structural normal anatomy withmoderately reduced contractility
while tachycardia. Laboratory studies including blood count,
inflammatory biomarkers and cardiac troponin were normal but
NT-proBNP was significantly elevated (maximum 2,685 pg/ml,
lab reference <130 pg/ml).
The initial 12-lead electrocardiogram (ECG) showed a regular,
sustained small-QRS-complex-tachycardia (mean heart-rate 240
beats/min). The tachycardia demonstrated a 1:1 atrio-ventricular
conduction (P-P cycle length 250ms) with a monomorphic P-
wave configuration characterized by a superior axis (P-vector
of −60◦) and sinus tachycardia was therefore not possible. RP
interval was significantly longer than PR—interval (i.e., long-RP-
tachycardia) and we thought about a permanent orthodromic
supraventricular tachycardia first (such as permanent junctional
reciprocating tachycardia) (Figure 1) and gave Adenosine
intravenously. This did not stop atrial tachycardia and ruled out
a reentry-tachycardia dependent on the AV-node. We therefore
hypothesized a focal ectopic atrial tachycardia. Infusion of
Flecainide (1 mg/kg/30min) did not affect the atrial rate or
atrioventricular conduction. Synchronized electric cardioversion
with 0.5 and 1 J/kg was performed due to signs of hemodynamic
instability but this just interrupted the tachycardia for seconds.
Medical cardioversion and rate control were attempted starting
Amiodarone with a bolus. After 30min the girl developed a
second-degree AV-block (type Wenckebach) with ongoing QRS-
amplitude alternans, eventually resulting in a bradycardia with 70
beats/min. Amiodarone infusion was stopped and the AV-block
resolved. While persisting EAT, Esmolol infusion was started and
slowly increased to a maximum rate of 75 mcg/kg/min. This
lowered the atrial tachycardia rate to 160 beats/min without
affecting the blood pressure. Ivabradine was started with a dose
of 0.25mg (0.025 mg/kg) every 12 h and increased to 0.5mg
(0.05 mg/kg) per dose on the second day. This led to a persistent
heart rate reduction to a physiologic level (80–100 beats/min
at rest) with alternating periods of restored sinus rhythm and
ectopic atrial rhythm. Subsequent ECG recordings showed sinus
rhythms with regular AV conduction and no abnormalities of de-
or repolarization (Figure 2). No adverse effects attributable to
Ivabradine were registered. After stabilization Esmolol infusion
was discontinued and the beta-blocker therapy was switched to
Metoprolol administered orally (1 mg/kg/d). Holter evaluation
before discharge (1 week after admission) showed sinus rhythm
with short times of ectopic atrial rhythm and a regular diurnal
pattern and heart rate.
In the follow up visits 2 and 10 weeks later echocardiography
showed normal left-ventricular function and dimension. The
12-lead-ECG and Holter evaluation showed alternating ectopic
atrial and sinus rhythm with a physiologic diurnal heart rate
spectrum and a regular response to physical activity (Figure 3).
Combination of Metoprolol and Ivabradine did not cause
bradycardia and no other side effects attributable to medication
were noticed.
DISCUSSION
We report a case of an 1-year old girl with EAT successfully
treated with a combination of beta-blocker and Ivabradine. EAT
is a rare cause of supraventricular tachycardia in children (1)
due to an ectopic rapid automatic atrial pacemaker (10) and it
can lead to a tachycardia induced cardiomyopathy (11). Familiar
cases of EAT with autosomal dominant inheritance have been
described, but family history was negative in our patient. As the
girl presented with supraventricular tachycardia, a moderately
reduced contractility and a preceding febrile infection, an acute
myocarditis could have been possible. However, there was no
further evidence for myocarditis.
Our patient presented with the characteristic ECG features of
an EAT showing a persisting atrial tachycardia with a variable
rate inappropriate for age. P-wave morphology depends on the
atrial origin and was in our case indicative for a origin from the
lower left septum or the ostium of the coronary sinus (Figure 1).
It usually differs from the P-wave morphology in sinus rhythm
although it can be difficult to differentiate atrial origins close
to the sinus node. Adenosine can be diagnostic as it induces
transient AV-block clearly showing the atrial tachycardia (12).
The clinical course of EAT differs between young children and
those 3 years and older (2). Antiarrhythmic medication can be
successful in young individuals with a rhythm control rate up
to 91% (2) and a spontaneous resolution of ∼50% during the
first year of life (13). However, a combination therapy of two or
more antiarrhythmics is needed in up to 50% of patients with
beta-blocker, Amiodarone, Digoxin, Flecainide, and Sotalol being
used (13). We used Flecainide as first line agent, which had no
effect on tachycardia in the reported case. Amiodarone, as added
intravenously, resulted in a bradycardia induced by an AV-block
and needed to be discontinued.
As a monotherapy with beta-blockers was not sufficient
for rate control we added Ivabradine. Reports on its use for
antiarrhythmic therapy in children are rare. Ivabradine however
has successfully been used as an addon-therapy in series of
drug-refractory infants with congenital JET (4, 5). Just as EAT,
congenital JET is caused by enhanced automaticity of cardiac
conduction tissue. It seems likely that ivabradine could therefore
be useful in patients with EAT too. There are first reports on
the efficacy of Ivabradine to control EAT in adult patients as
well as in older children and adolescents (6–9). On this basis
we started oral Ivabradine in our young patient and restored
sinus rhythm within 2 days by a combination therapy with
metoprolol. As beta-blocker therapy is established and usually
well-tolerated in infants and young children we decided to use
Ivabradine not as monotherapy, but in addition to Metoprolol.
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FIGURE 1 | Initial presentation: 12-lead-ECG with a regular sustained small QRS-Complex tachycardia, P-vector −60◦, a delay of the atrioventricular conduction,
RP > PR and a QRS-complex amplitude alternans.
FIGURE 2 | ECG recordings at different time points of the therapy showing no significant changes in the time intervals and de- or repolarisation. (A) Monotherapy with
Esmolol before start of Ivabradine. Time intervals PQ 120ms, QRS 60ms, QT 260ms, QTcB 427ms. (B) After start of Ivabradine, in combination therapy with
Esmolol. Time intervals PQ 110ms, QRS 65ms, QT 270ms, QTcB 417ms. (C) Follow up after 10 weeks combination therapy Ivabradine with Metoprolol. Time
intervals PQ 110ms, QRS 60ms, QT 280ms, QTcB 404ms.
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FIGURE 3 | Holter recording (follow up). (A) 24 h Heart rate recording showing a physiologic diurnal heart rate spectrum (heart rate maximum 157 beats/min,
minimum 90 beats/min, mean 116 beats/min). (B) ECG with alternating sinus rhythm and ectopic atrial rhythm during a period with physical activity and accelerated
heart rate in the afternoon (4.00–6.00 pm).
This combination of Ivabradine and beta-blocker was effective
and did not cause bradycardia.
In infants and young children, the anatomic substrate of EAT
is different compared to older patients. It has been hypothesized
that EAT in small individuals is based on abnormal embryonic
cells with enhanced automaticity (14) and is linked with a high
risk for complications during catheter ablation due to the low
body weight of these children. As spontaneous resolution of the
tachycardia is more likely, initially medical treatment is usually
preferred. In this context our report adds the second case of an
ectopic atrial tachycardia in this age group successfully controlled
with Ivabradine to the existing literature. Ivabradine seems to
be a promising treatment option in pediatric arrhythmia due to
increased automaticity.
No relevant cardiac side-effects attributable to Ivabradine
were noticed in our patient during follow-up. This is in
concordance with the existing reports supporting Ivabradine
as a safe treatment option, but data on its use especially in
younger children is very rare. Clinical studies are needed to
evaluate its safety and effectiveness systematically compared to
standard regimes in the treatment of tachycardia in the pediatric
age group.
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